Humedix KRX:200670KOSDAQ
휴메딕스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days3
Articles tracked0since Sep 11
In Q2 2026, Humedix reported revenue of ₩50.4bn, up 17.3% year on year, and operating profit of ₩11.7bn. Humedix (휴메딕스) appeared in 0 Korean news articles and 3 DART filings over the past seven days.
Humedix quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩50.4bn | +17.3% | ₩11.7bn | ₩2.4bn |
| Q1 2026 | ₩40.5bn | +1.0% | ₩8.9bn | ₩13.0bn |
| Q4 2025 derived | ₩46.0bn | +22.8% | ₩11.1bn | ₩7.8bn |
| Q3 2025 | ₩40.9bn | +9.5% | ₩9.0bn | ₩22.7bn |
| Q2 2025 | ₩43.0bn | -6.3% | ₩10.8bn | ₩7.9bn |
| Q1 2025 | ₩40.1bn | -2.5% | ₩11.4bn | ₩13.4bn |
| Q4 2024 derived | ₩37.5bn | +2.0% | ₩10.2bn | ₩11.3bn |
| Q3 2024 | ₩37.4bn | -5.8% | ₩9.2bn | ₩6.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Humedix top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Humedix news Korean headlines
No articles yet.